About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Combination Therapy may Not Help in Treatment of Endocrine Resistant Breast Cancer Cells

by Kathy Jones on April 5, 2012 at 9:22 PM
Font : A-A+

 Combination Therapy may Not Help in Treatment of Endocrine Resistant Breast Cancer Cells

Researchers at Georgetown Lombardi Comprehensive Cancer Center have warned that a new class of agents known as c-Src inhibitors should not be used in combination with estrogen to treat endocrine resistant breast cancer.

That's because their new study, being reported at the American Association for Cancer Research (AACR) Annual Meeting 2012, shows that using estrogen and a c-Src inhibitor, PP2, cancel each other out. The benefit once seen in using estrogen was gone once PP2, an inhibitor of the Src-family of kinases used for laboratory studies, was added.

Advertisement

Instead, the findings suggest that using a c-Src inhibitor alone may offer another treatment option to estrogen-receptor-positive breast cancer patients whose tumor no longer responds to tamoxifen or aromatase inhibitors, explains the study's lead researcher, Ping Fan, Ph.D. Her research is conducted in the lab of V. Craig Jordan, OBE, PhD, DSc, FMedSci, scientific director at Georgetown Lombardi.

Most c-Src inhibitors have been approved for use in blood cancers and some are now being tested in solid cancers including breast cancer. C-Src helps control signaling pathways associated with growth, survival and cell migration, and increased activity of this protein has been observed in multiple tumor types.
Advertisement

The study results came about because a Georgetown Lombardi research team, led by Jordan, was testing whether a combination of estrogen and PP2, an inhibitor of c-Src used in laboratory experiments, could work synergistically to destroy breast cancer cells that no longer responded to endocrine therapy.

Clinical studies have shown that, for reasons that have not been fully explained yet, about 30 percent of endocrine resistant breast tumors respond to low doses of estrogen. The Georgetown Lombardi study was designed to see if using PP2 with estrogen could produce a stronger therapeutic outcome.

What they found was unexpected  there was less, not more, of a killing effect when the two drugs were used together in the lab. Further investigation concluded that c-Src, one of the family of Src kinases inhibited by PP2, "is one of the important molecules in estrogen-stimulated pathways, so using an inhibitor of c-Src eliminates the beneficial effect of estrogen," says Fan.

They also found evidence that estrogen induces expression of multiple genes that act en masse to kill breast cancer cells.

"Our data suggest these two drugs should not be used together in resistant cancers," Fan says.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Top 9 Reasons Why We Should Practice Kindness
Top 10 Vitamin B12 Foods for Vegetarians - Slideshow
Targeted Screening Program Beneficial for Prostate Cancer Screening
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Parkinsons Disease Surgical Treatment Pheromones Reiki and Pranic Healing Breast Cancer Facts Cancer Facts 

Most Popular on Medindia

Sinopril (2mg) (Lacidipine) Selfie Addiction Calculator Find a Hospital Daily Calorie Requirements Nutam (400mg) (Piracetam) Drug Interaction Checker Blood Pressure Calculator Pregnancy Confirmation Calculator Vent Forte (Theophylline) Noscaphene (Noscapine)

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use